Literature DB >> 19942481

Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis.

Kjell Fuxe1, Daniel Marcellino, Giuseppina Leo, Luigi F Agnati.   

Abstract

The intramembrane receptor-receptor interactions among GPCRs demonstrated in the beginning of the 80s in the CNS probably reflect the existence of allosteric mechanisms in receptor heteromers, and the postulated assemblies of multiple GPCRs coined 'receptor mosaics' in the early 80s probably represent higher order receptor heteromers, recently demonstrated with novel biophysical techniques in living cells. The receptor interface in the GPCR heteromers is beginning to be characterized and in adenosine A(2A)-dopamine D(2)-like heteromers the electrostatic arginine-phosphate salt bridge seems to be a hot spot in the interface with covalent-like stability, possibly participating in the allosteric interactions and making possible integration of heteromer receptor function. We discuss the possible relevance of some putative D(2) receptor heteromers in the treatment of Parkinson's disease and schizophrenia, respectively. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942481     DOI: 10.1016/j.coph.2009.10.010

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  33 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

Review 3.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 4.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 5.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

Review 6.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 7.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

8.  Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes.

Authors:  Chiara Cervetto; Arianna Venturini; Diego Guidolin; Guido Maura; Mario Passalacqua; Carlo Tacchetti; Pietro Cortelli; Susanna Genedani; Simona Candiani; Paola Ramoino; Simone Pelassa; Manuela Marcoli; Luigi F Agnati
Journal:  J Mol Neurosci       Date:  2018-07-20       Impact factor: 3.444

9.  Dopamine D2L Receptor Deficiency Causes Stress Vulnerability through 5-HT1A Receptor Dysfunction in Serotonergic Neurons.

Authors:  Norifumi Shioda; Yoshiki Imai; Yasushi Yabuki; Wataru Sugimoto; Kouya Yamaguchi; Yanyan Wang; Takatoshi Hikida; Toshikuni Sasaoka; Michihiro Mieda; Kohji Fukunaga
Journal:  J Neurosci       Date:  2019-08-01       Impact factor: 6.167

10.  Oligomerization of G-protein-coupled receptors: a reality.

Authors:  Sergi Ferré; Rafael Franco
Journal:  Curr Opin Pharmacol       Date:  2009-12-16       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.